Anti-PD-1 therapy in advanced sarcomas: is cutaneous primary site a stronger predictor of response than histologic subtype?

BACKGROUND: Immune checkpoint inhibitors (ICIs) have shown modest antitumor activity in unselected advanced sarcomas. Histology driven approach to patient selection is the current standard for off-label anti-programmed cell death 1 (PD1) immunotherapy use. METHODS: We retrospectively reviewed the cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Miao, Ruoyu, Swank, Jennifer, Melzer, Dan, Ludlow, Steven, Clark, Leah, Finger, Molly, Reed, Damon R., Druta, Mihaela, Brohl, Andrew S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264480/
https://www.ncbi.nlm.nih.gov/pubmed/36912932
http://dx.doi.org/10.1007/s00262-023-03387-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264480/
https://www.ncbi.nlm.nih.gov/pubmed/36912932
http://dx.doi.org/10.1007/s00262-023-03387-6

Ejemplares similares